New investment for the development of the handheld diagnostic and monitoring device Enzyre

Enzyre, a spin-out from the Radboud University Medical Center in the Netherlands, was founded to develop an innovative Near Patient Test (NPT) device called Enzypad to measure biomarkers in body fluids. There is a growing need for NPT tools that enable patients and healthcare professionals to deliver remote, personalized and data-based care, reducing hospital visits and healthcare costs.

The first application of Enzypad will significantly change the quality of life of haemophilia patients by providing a real-time picture of a patient's blood clotting status. The result of each test performed by a patient is automatically sent to the treating physicians via an app on a mobile phone. In December 2019, Enzyre signed a partnership with Takeda to develop Enzypad for congenital blood disorders, validating this innovative approach.   The Cabinet has made 300 million euros available for bridging loans for start-ups, scale-ups and (innovative) SMEs. OostNL awarded the Corona Bridging Loan (COL) to Enzyre. Novalis Biotechnology Incubation acted as co-funder.   CEO Dirk Pollet of Enzyre: "The Corona Bridge Loan gives us the time to continue our development. In addition, we are pleased to welcome Novalis Biotechnology Incubation as an investor. The Novalis team is very well aligned with Enzyre's strategy to" bring the laboratory to the patient ", thus avoiding hospital visits. We believe there is a tremendous demand for technology that enables patients to provide the best therapy without delay and higher costs. The Enzypad is able to to meet this demand. "   Prof. Wim Van Criekinge of Novalis added: "Testing patients in the neighbourhood today offers a great opportunity to achieve better treatment outcomes for patients. More and better data are an essential element in our drive to advance healthcare. We were impressed by the Enzyre team and the Enzypad technology, which has many application areas beyond coagulation testing Our investment in Enzyre is a perfect fit with our strategy to invest in innovative breakthrough technology in the life sciences.